Abstract. Accumulating epidemiologic and preclinical evidence support the pharmacologic use of a variety of dietary chemicals for the prevention and treatment of cancer. However, it will be challenging to translate these findings into routine clinical practice since phytochemicals have pleiotropic biological activities that have to be balanced for optimal efficacy without unacceptable and potentially unanticipated toxicities. Correctly matching patient populations and settings with optimal, natural product-based phytochemical therapies will require a greater understanding of the specific mechanisms underlying the efficacy, toxicity, and resistance of each agent in a variety of normal, premalignant, and malignant settings. This, in turn, necessitates continued commitment from the basic research community to guide carefully designed and informed clinical trials. The most developed class of anticancer phytochemicals consists of the derivatives of vitamin A called retinoids. Unlike other natural product chemicals currently under study, the retinoids have been extensively tested in humans. Over 30 years of clinical investigation has resulted in several disappointments, but there were some spectacular successes where certain retinoid-based protocols are now FDA-approved standard of care therapies to treat specific malignancies. Furthermore, retinoids are one of the most evaluated pharmacologic agents in the ultra-challenging setting of interventional cancer prevention. This review will summarize the development of retinoids in cancer therapy and prevention with an emphasis on currently proposed mechanisms mediating their efficacy, toxicity, and resistance.
INTRODUCTION
Retinoids are natural and synthetic derivatives of vitamin A. Natural vitamin A derivatives have important roles in regulating embryonic development, germ cell homeostasis, and maintenance of healthy tissue and epithelium (1) . Unlike other dietary phytochemicals proposed to be cancer-preventive agents primarily due to detoxifying and antioxidant properties, retinoids have been rationalized as anticancer agents mainly for their inductive effects on cellular differentiation and growth suppression (2, 3) . It is well established that retinoids directly regulate transcription through specific and high-affinity interactions with nuclear receptor transcription factors (4, 5) .
The structure of retinoids consists of a cyclic end group, a polyene side chain, and a polar end group. Several thousand synthetic derivatives of retinoids exist based on modifications of these functional groups (6) (Fig. 1 ). Since retinoids cannot be synthesized de novo in animals, the only source is dietary intake. Retinoids can be acquired in the form of provitamin A carotenoids present in a variety of vegetables and fruits. The carotenoid precursors of retinoids include β-carotene, which is the most potent form, as well as α-carotene and β-cryptoxanthin (7, 8) . β-carotene is a phytochemical of the terpene (isoprenoid) class and is a well-known antioxidant. Alternatively, retinoids can be obtained from preformed retinoids such as retinyl ester (retinyl palmitate) and retinol in foods of animal origin such as liver, meat, milk, and eggs (7, 8) .
β-carotene and esterified retinol are converted to retinol in the intestine. It is then re-esterified and transported by chylomicrons to the liver for storage in stellate cells (9, 10) . Retinol released by the liver is bound to serum retinolbinding protein (RBP) and transported to all tissues in the blood (11) . Retinol enters cells via RBP binding to the transmembrane protein STRA6 (12) . Once retinol is delivered to cells, it is enzymatically converted first to retinaldehyde and then to the biologically active derivative all-trans retinoic acid (RA), which can isomerize to 9-cis retinoic acid and 13-cis retinoic acid (9, 10) . RA binds to two cytosolic binding proteins, cellular retinoic acid binding protein I (CRABPI) and cellular retinoic acid binding protein II (CRABPII) (13) . It is proposed that CRABPI functions primarily to sequester RA and to promote its metabolism, while CRABPII delivers RA to the nucleus and nuclear receptors (13) . RA is degraded to polar byproducts primarily by CYP26A1 and excreted from cells or further degraded (14, 15) . In addition to the natural bioactive retinoic acid derivatives, a major effort has been made to design synthetic retinoids that have unique properties and are selective for distinct retinoid receptors (6) .
HISTORY OF RETINOIDS IN CANCER
Wolbach and Howe reported in 1925 that rats lacking vitamin A in their diet developed lesions of the aerodigestive tract, reminiscent of metaplastic lesions of smokers (16) . These lesions were reversible with dietary supplements of vitamin A, suggesting that systemic retinoids could lead to normalization of precancerous epithelium (16) . Several reports noted an inverse relationship between dietary vitamin A intake or serum retinol levels and the incidence of certain malignancies (17) . Beginning in the 1970s, it was established that natural and synthetic retinoids could reduce the incidence of spontaneous and carcinogen-induced cancers in animal models (18, 19) . In the early 1980s, small-scale trials utilizing high-dose retinoids demonstrated clinical activity in the treatment of preneoplastic diseases including oral leukoplakia, cervical dysplasia, and xeroderma pigmentosum (20, 21) . High-dose retinoids were also reported to reduce subsequent malignancies of the liver, head and neck, lung, and breast (21) . The most successful use of retinoids has been RA-based differentiation therapy for acute promyelocytic leukemia (APL) (22) . Retinoids are also known to be active in other overt malignancies such as juvenile chronic myelogenous leukemia, Kaposi's sarcoma, neuroblastoma, and cutaneous T cell lymphoma (20, 23) . Despite this extensive preclinical, epidemiological, and early clinical evidence for retinoids in cancer treatment and prevention, several more recent large-scale retinoid trials failed to show therapeutic benefit (24) (25) (26) . This is likely due to a number of factors including failure to use the optimal retinoid form, suboptimal trial design, dose reduction due to toxicity of long-term treatments, retinoid resistance, repression of retinoid receptor expression, and the unanticipated toxicity of retinoids when combined with tobacco smoke (20, 27) .
RETINOID MECHANISMS OF ACTION

Retinoids as Transcription Regulators and Epigenetic Modifiers
The biological effects of retinoids are mediated primarily through binding to two distinct classes of nuclear receptors, retinoic acid receptors (RARs) and retinoic X receptors (RXRs) (4, 5) . As ligand-dependent transcriptional regulators, RARs and RXRs are both activated by 9-cis retinoic acid, while all-trans retinoic acid binds specifically to RARs (28, 29) . Each class of receptor contains three distinct gene products, α, β, and γ, which can be expressed as multiple isoforms with distinct regulatory and functional properties (4, 5) . Two major isoforms have been identified for RARα, RARγ, RXRα, RXRβ, and RXRγ, whereas RARβ was found to have four major isoforms (28, 29) . These isoforms exist through alternative splicing and differential promoter usage. Distinct differences in the ligand-binding domains have allowed the design of specific pharmacologic activators of RARα, RARβ, and RARγ, as well as synthetic ligands specific to RXRs (6) .
RARs and RXRs form heterodimers that activate transcription of downstream target genes (28, 29) . Direct target genes of RARs include genes involved in retinoid signaling, such as RARβ, CRABPII, RIP140, and CYP26A1 (30, 31) . The receptor complexes specifically bind to retinoic acid response elements (RAREs) that are composed of two direct repeats of a core hexameric motif separated by 1, 2, or 5 nucleotides (4, 28, 29) . RAREs have been identified in the promoters of a number of RA target genes implicated in various biological processes such as signal transduction, protein modification, metabolism, and developmental regulation (30, 32) . Moreover, advances in high-throughput technology such as chromatin immunoprecipitation coupled with deep sequencing have revealed new RAR-binding loci and alternative DNA binding elements (32, 33) .
The transcriptional regulation of RA target genes by retinoid receptors is dependent on ligand-induced conformational changes that control the dynamics of coregulators. In the absence of ligand, DNA-bound RAR-RXR heterodimers are associated with corepressors such as nuclear receptor corepressor or silencing mediator of RAR and thyroid receptor, that serve as adaptors to recruit protein complexes endowed with histone deacetylase activity (34, 35) . As a result, chromatin structure is condensed and transcription is repressed. Upon ligand-binding, RARs undergo conformational changes allowing corepressors to be released and, in turn, recruiting coactivators such as the p160 subfamily of steroid receptor coactivators (SRCs), including SRC-1, -2, and -3 (34, 35) . Similar to corepressors, coactivators serve as adaptor proteins that recruit large complexes with distinct enzymatic activities, such as histone acetyltransferases, histone methyltransferases, histone demethylases, ubiquitinases/ deubiquitinases, and DNA-dependent ATPases (34, 35) . These complexes lead to chromatin decondensation and recruitment of the machinery to enhance transcription (36) .
In addition to classical coactivators and corepressors, a third class of coregulators consists of the ligand-dependent corepressors, which include RIP140, LCor, and PRAME (37) . It has been shown that these coregulators bind to RARs in the presence of ligand but repress transcription through the recruitment of histone deactylases and C-terminal binding proteins (37) . Work in our laboratory demonstrated that RIP140 itself is a direct transcriptional target of RA and that it functions to limit retinoid signaling, comprising a negative feedback mechanism that is relevant to the biological activity of RA (38, 39) . Furthermore, RIP140 is involved in the oscillatory expression of RA target genes in the constant presence of ligand (40) . Depletion of RIP140 through siRNA sensitizes human embryonal carcinoma cells to the antiproliferative and differentiation effects of RA and is a mechanism of crosstalk between RA and estrogen receptor signaling (39, 41) . Genome-wide studies indicate that RIP140 discriminates between different classes of RA target genes (42) .
Retinoid-mediated transcriptional changes are linked to changes in epigenetic marks on histones and DNA through retinoid-induced recruitment of epigenetic modifying enzymes. For example, in undifferentiated embryonic stem (ES) cells, the HOXA1 and HOXB1 genes involved in development and cell fate decisions are repressed and trimethylated at lysine 27 on histone 3 (H3K27me3) (43) . Upon RA addition, this repressive histone mark decreases, followed by an increase in H3K4 methylation and H3 acetylation, both of which are associated with transcriptional activation (43, 44) . Important mediators of the epigenetic changes induced by RA are polycomb group repressive complexes (PRC1 and PRC2), which are associated with gene silencing in ES cells (44, 45) . High-throughput genome-wide analyses have revealed changes in the protein composition of PRC1 upon RA treatment, resulting in differential recruitment of PRC1 to distinct gene subsets in pluripotent and differentiating ES cells (44) (45) (46) . These findings demonstrate specific epigenetic mechanisms employed by stem cells during RA-induced differentiation (45) . It is important to note that several enzymes that alter histone modifications and DNA methylation are themselves direct or indirect target genes of RA (44, 45, 47) . A role for microRNAs and DNA methylation in controlling retinoid-dependent differentiation has also recently emerged (45, 48, 49) .
Retinoids as Inducers of Differentiation
A major driver of retinoid anticancer effects is through inducing tumor cell differentiation (50, 51) . Well-characterized model systems for investigating the role of RA in cell differentiation in vitro are ES cells and embryonal carcinoma (EC) cells, both of which are undifferentiated, self-renewing, and pluripotent (52, 53) . RA treatment of ES cells in combination with appropriate growth factors and/or specific culture conditions results in distinct cell types such as neurons, glial cells, adipocytes, chondrocytes, osteocytes, corneal epithelium, skeletal muscle, smooth muscle, and ventricular cardiomyocytes, as reviewed (52) .
The major cell models of RA-induced differentiation of EC cells are murine F9 and P19 cells and human NT2/D1 cells (54) (55) (56) . Our laboratory has extensively studied RAinduced differentiation of the human EC cell line, NT2/D1 (31, 42, 53) . Human EC cells display distinct genetic, phenotypic, and biologic features as compared to murine EC cells and serve as a valuable and practical complement to human ES cells that reflect early human development (53, 55) . NT2/ D1 cells commit to terminally differentiate toward a neuronal lineage within 48 h of RA treatment (55, 57) . This is associated with ubiquitin-dependent degradation of cyclin D1, remodeling of Wnt signaling, and activation of p53 (58) (59) (60) . A critical role for p53 in repressing pluripotency reprogramming has recently been uncovered (61) . In order to understand the underlying mechanism of RA-associated differentiation, it is important to identify those genes whose expression is altered directly by RA. Large-scale cDNA microarray technology has identified early downstream targets of RA prior to, or concurrent with, commitment of NT2/ D1 cells to enter a program of differentiation (31, 62) . Many of these gene products are associated with developmental pathways including those of TGF-β, homeodomain, IGF, Notch, Hedgehog, and Wnt signaling (31) . Retinoids initiate the regulation of direct target genes and subsequently, a cascade of secondary response genes, leading to the differentiation of both pluripotent stem cells and many types of lineage-restricted progenitor cells (33, 45, 47, 63) .
In addition to transcriptional activation, RA signaling is implicated in the control of transcriptional repression. One of the early actions of RA is to promote the repression of pluripotency genes required for the maintenance of the pluripotent state (45, 47, 64) . Our laboratory and others have observed that RA treatment represses a cassette of candidate pluripotency genes on chromosome 12p13 in NT2/D1 cells (57, 65) . These genes include NANOG, GDF3, DPPA3, PHC1, GLUT3, APOBEC1, and CD9, which are associated with regulation of stem cell renewal, as reviewed (66) . However, the precise molecular mechanisms underlying this gene repression by RA are not known. One proposed model suggests that pluripotency genes SOX2, NANOG, and OCT4 are inhibited by RA-induction of the orphan nuclear receptor GCNF, allowing stem cells to forfeit self-renewal and differentiate (67) .
Alternative non-genomic and rapid non-canonical models of RA signaling have expanded the scope of the biological actions of retinoids (68) (69) (70) . These include mechanisms involving cytosolic and membrane actions of RARs that regulate PI3K, AP1, and NFκB pathways (68) (69) (70) . In addition, RAR-dependent mechanisms involving modulation of the activities of ERK, JNK, PKCα, and reactive oxygen species have been uncovered (68) (69) (70) . RA can also reportedly interact with other members of the steroid nuclear receptor family including PPARβ/δ and RORβ (71, 72) .
CLINICAL USE OF RETINOIDS IN CANCER THERAPY AND PREVENTION
Over 30 years of intensive clinical investigation aiming to harness the potent anticancer effects of retinoids has resulted in examples where retinoids have been incorporated into the standard of care (Table I ). There are also many cancer types that have responded to high-dose retinoids in vitro and in small-scale clinical trials, but are not currently treated with these agents (Table I) . Representative examples are now discussed.
All-trans RA is a FDA approved, standard of caretargeted therapy for APL associated with induced differentiation of promyelocytes and increased rates of remission (22) . The combination of RA and anthracycline-based therapy results in long-term survival in greater than 80% of APL cases, as compared to 40% of cases treated with anthracycline alone (22) . In addition, a recent randomized phase III trial showed therapeutic benefit of combining RA with arsenic trioxide treatment for low to intermediate risk APL patients without DNA-damaging chemotherapy (73) . For high-risk neuroblastoma, the standard treatment regimen consists of myeloablative therapy and autologous stem cell rescue followed by maintenance therapy with 13-cis retinoic acid (isotretinoin) that aims to treat minimal residual disease (74) . The synthetic retinoid fenretinide (4-HPR), as well as the combination of 13-cis RA with other cytotoxic, biologic, and immunotherapies, is currently undergoing testing for maintenance therapy of high-risk neuroblastoma (75) . Bexarotene (Targretin), a synthetic RXR-specific rexinoid, is FDA approved for the treatment of early and advanced stage cutaneous T cell lymphoma, particularly for patients whose disease is refractory to at least one prior therapy (76) . The retinoid, 9-cis retinoic acid (alitretinoin) is also FDA approved for the topical treatment of Kaposi's sarcoma (77) .
Retinoids were one of the first proofs of principles for chemoprevention, the concept of using natural, synthetic, or biochemical agents for the purpose of reversing, suppressing, or preventing carcinogenic progression (78) . The focus on retinoids in prevention came from epidemiologic data that antioxidants found in fruit and vegetables, including β-carotene, were inversely associated with cancer risk and basic research establishing that retinoids can induce cellular differentiation and growth suppression of premalignant and malignant cells (17) . Translational studies with retinoids set the early standard for molecularly targeted research in cancer prevention and retinoids remain one of the most studied natural product-based preventive agents in humans (21) . Trials with retinoids have been conducted in the settings of primary prevention in healthy individuals at high cancer risk, secondary prevention in patients with premalignant disease, and tertiary prevention of second primary tumors (79) . A large-scale phase III study showed that the synthetic retinoid fenretinide administered for 5 years could protect women aged 40 years or younger from breast cancer recurrence and possibly ovarian cancer for up to 10 years after retinoid cessation (80) . A primary, multicenter randomized fenretinide trial of healthy young women at high risk (i.e., those with germline BRCA-1 and BRCA-2 mutations) for breast cancer has been initiated (81) . A controlled prospective study of 13-cis retinoic acid showed a significant reduction in skin cancer in patients with xeroderma pigmentosum during 2 years of treatment, but had a considerable number of associated toxicities (82) . In addition, a large randomized trial found systemic retinol to significantly lower the risk of developing new squamous cell carcinomas (83) . Systemic retinoids such as acitretin are widely used in organ transplant recipients at high risk for developing multiple non-melanoma skin cancers, although further randomized trials are required to definitively establish the safety and efficacy of retinoids in this setting (84) . The synthetic retinoid etretinate (Tigason) and acyclic retinoid (polyprenoic acid) have shown promising results in improving recurrence rates in bladder cancer and hepatocellular carcinoma, respectively (85) (86) (87) .
As can be appreciated in the preceding sections, retinoids have demonstrated clinical benefits as anticancer agents. However, these examples are fewer in number as compared to the known potent and broad anticancer properties of retinoids demonstrated in preclinical and small-scale, short-term efficacy trials. For example, smallscale randomized trials with retinoids alone and in combination with other agents showed promising activity in the prevention of oral leukoplakia and the treatment and prevention of secondary head and neck and lung cancers (17, 21, 88, 89) . However, several subsequent large-scale phase III trials failed to show a clinical benefit in these settings (20, 21) . More surprisingly, two large randomized primary prevention trials reported the unexpected finding that lung cancer incidence and mortality increased in high-risk patients who were administered high-dose β-carotene plus vitamin E or β-carotene plus retinol (90, 91) .
LESSONS LEARNED FROM THE CLINICAL DEVELOPMENT OF RETINOIDS
Retinoids can be viewed as a paradigm for the translation of natural phytochemicals to the cancer clinic. The challenge going forward is to better translate preclinical and early phase trial success into widespread clinical utility. One approach to increase the efficacy of retinoids is through combination therapy. Retinoids and other phytochemicals are (19) . One important lesson learned is the importance of choosing retinoid and retinoid combinations based on established efficacy in preclinical and animal models of human cancer (18) (19) (20) (21) . The example of β-carotene that was entered into large-scale primary prevention trials based mainly on epidemiologic studies is a case in point (17, 90, 91) . Another important issue is dose and the trade-off between efficacy and toxicity. Retinoids frequently showed impressive therapeutic and preventive properties when given at high, maximally tolerated doses in short-term studies, but failed to exhibit efficacy in subsequent large-scale, longterm trials that required dose reduction due to toxicity (20, 21) . In many situations, retinoids have been shown to be more effective when used earlier in the carcinogenic continuum as in the prevention of secondary cancers or in the treatment of premalignancy or minimal residual disease (79, 92) . However, it is in these settings where toxicity is least tolerated. This will be an issue for all phytochemicals to various extents, in addition to the issue of unanticipated side effects and harmful interactions as in the case of β-carotene and smoking. A related challenge is the reversibility of retinoids, and likely other phytochemicals, that will necessitate long-term therapies (20, 21) . Systematic study of retinoid scheduling in animal models and early clinical trials may prove to be a fruitful approach to optimize retinoid use in the clinic. In certain cases, it has been found that high, intermittent doses of retinoids are more effective than low-dose continuous therapy. One successful example that incorporates this concept is the high, intermittent dosing of 13-cis retinoic acid to treat minimal residual disease in neuroblastoma (74) . Information from biomarker analyses has increasingly been used to guide the design of retinoid trials. It is challenging to identify a clinically valid biomarker. One attractive approach to identify reliable biomarkers is the use of extensive preclinical and animal studies to identify potential targets and biomarkers that predict response. Then, these markers are validated in phase 0 window of opportunity trials (93, 94) . Phase 0 trials are also useful for assessing whether intratumoral drug concentrations are attained and have effects on the target of interest. Another approach is to conduct retrospective pharmacogenomics studies that can associate distinct genetic loci with therapeutic efficacy (95, 96) . These approaches will likely be advantageous in the future to broadly and successfully utilize retinoids in the treatment and prevention of cancer.
Phase 0, window of opportunity trials in lung cancer showed that the rexinoid bexarotene plus the epidermal growth factor receptor (EGFR) inhibitor erlotnib had clinical activity (93) . Analysis of pre-and post-biopsy specimens indicated that repression of cyclin D1 and therapeutic intratumoral levels of bexarotene were biomarkers of response. A subsequent phase II trial with bexarotene plus erlotnib produced major clinical anticancer responses with prolonged progression-free survival (94) . Hypertriglyceridemia was associated with an increased median overall survival, which was also seen in trials that combined bexarotene with chemotherapy in non-small cell lung cancer (NSCLC) patients (94, 97, 98) . These results suggest that hypertriglyceridemia is another clinically relevant marker of effective bexarotene therapy.
The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial tested the potential of prospectively stratifying patients for retinoid therapy (99) . Advanced NSCLC patients whose tumors had high levels of cyclin D1 and wild-type EGFR were treated with the combination of bexarotene and erlotnib, while patients with EGFR mutations were given erlotnib only. Bexarotene plus erlotnib had significant activity in patients whose tumors overexpressed cyclin D1 as compared to those cases on erlotnib therapy alone (99) . An interesting prospective BATTLE prevention trial is currently being planned where patients with resectable NSCLC will be randomized to chemoprevention protocols based on their marker profile (100). Those with overexpression of cyclin D1 will receive erlotnib and bexarotene and the endpoint will be cancer recurrence.
Two retrospective pharmacogenomics studies have highlighted the potential use of single nucleotide polymorphisms (SNPs) to guide retinoid prevention trials. One study assessed SNPs of the mTOR pathway and found that head and neck cancer patients carrying five high-risk loci showed the greatest benefit from 13-cis retinoic acid therapy (95) . A second study genotyped over 9,000 SNPs and found a combination of three loci that was associated with a substantial reduction in head and neck cancer recurrence following 13-cis retinoic acid treatment (96) . These retrospective studies indicate that a pharmacogenetic approach may help select head and neck cancer patients for chemoprevention with 13-cis retinoic acid. This general strategy has the potential to improve the overall efficacy of retinoids and other phytochemicals in cancer therapy and prevention.
CONCLUSIONS
Dietary phytochemicals and other natural products have recently shown promise as cancer-preventive agents. However, the clinical development of these agents will likely be challenging due to concerns associated with unwanted or unanticipated toxicities during long-term effective dosing. As exemplified in the clinical development of the retinoids, the best path forward should involve careful trial design that incorporates evaluation of drug delivery, assessment of successful drug targeting, and selection of patients who will most likely benefit based on biologic and genetic biomarkers. Further basic and translational research to enhance the understanding of mechanisms, targets, and biomarkers will be necessary for dietary anticancer agents to reach their full potential.
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